A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors (NCT07090499)
A Phase 1 Open-label Study to Investigate PF-08046876 in Adult Participants With Advanced Solid Tumors.
🩺 Plain-English Summary (8th-Grade Level)
The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs are anticancer drugs designed to stick to cancer cells and kill them. The study drug will be given to participants through a needle in a vein (intravenous infusion). This study includes multiple parts. In the first part of the study, there will be different groups of people receiving different doses of the study drug. The study may also test different schedules.
Who can join: Review the eligibility criteria below.
Location: City of Hope National Medical Center — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (30 Sites)
Showing the first 25 of 30 sites.
- City of Hope National Medical Center — Duarte, California
- City of Hope at Irvine Lennar — Irvine, California
- Ronald Reagan UCLA Medical Center — Los Angeles, California
- UCLA Department of Medicine-Hematology/Oncology — Los Angeles, California
- Santa Monica UCLA Medical Center & Orthopaedic Hospital — Santa Monica, California
- UCLA Hematology/Oncology - Santa Monica — Santa Monica, California
- Smilow Cancer Hospital - Yale New Haven Health — New Haven, Connecticut
- Yale - New Haven Hospital - Yale Cancer Center — New Haven, Connecticut
- Smilow Cancer Hospital Phase 1 Unit — New Haven, Connecticut
- Smilow Cancer Hospital - Trumbull — Trumbull, Connecticut
- Brigham and Women's Hospital — Boston, Massachusetts
- Dana-Farber Cancer Institute — Boston, Massachusetts
- Dana-Farber Cancer Institute - Chestnut Hill — Newton, Massachusetts
- Sarah Cannon Research Institute - Pharmacy — Nashville, Tennessee
- SCRI Oncology Partners — Nashville, Tennessee
- The University of Texas MD Anderson Cancer Center - Conroe — Conroe, Texas
- University of Texas MD Anderson Cancer Center — Houston, Texas
- The University of Texas, MD Anderson Cancer Center - West Houston — Houston, Texas
- The University of Texas, MD Anderson Cancer Center - League City — League City, Texas
- NEXT Oncology — San Antonio, Texas
- The University of Texas, MD Anderson Cancer Center - Sugar Land — Sugar Land, Texas
- Princess Margaret Cancer Centre — Toronto, Ontario
- Princess Margaret Cancer Centre — Toronto, Ontario
- McGill University Health Centre — Montreal, Quebec
- Pan American Center for Oncology Trials, LLC — Rio Piedras,
📞 Contact the Study Coordinator
Phone: (800) 718-1021
Email: ClinicalTrials.gov_Inquiries@pfizer.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced/Metastatic Solid Tumors
- A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors — La Jolla, California
- ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors — Scottsdale, Arizona
- A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors — Los Angeles, California
Explore by condition: All Advanced/Metastatic Solid Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.